Showing results (1-10 of 49) with videos related to
Sort By:
Pageof 5
The Journal of Infection|October 21, 2009
Serial knife stabbings with HIV exposure--implications for post-exposure prophylaxisPernille Jorgensen, Ulrich Marcus, Helmut Albrecht, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 17, 2005
Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapyTobias Welte, Wolfgang Petermann, Dirk Schürmann, et al.The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 26, 2008
Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in GermanyDirk Schürmann, Sonja V Sorensen, Erwin De Cock, et al.Infection|July 28, 2020
HIV transmission by human bite: a case report and review of the literature-implications for post-exposure prophylaxisDirk Schürmann, Christian Hoffmann, Miriam S Stegemann, et al.International Journal of Chronic Obstructive Pulmonary Disease|September 7, 2023
Uncapped Metered-Dose Inhalers: A Risk for Foreign Body Aspiration. A Case Report and Review of the LiteratureDirk Schürmann, Jacopo Saccomanno, Bettina Temmesfeld-Wollbrück, et al.Virus Genes|April 19, 2007
Transmembrane protein polymorphisms and resistance to T-20 (Enfuvirtide, Fuzeon) in HIV-1 infected therapy-naive seroconverters and AIDS patients under HAART-T-20 therapyVladimir A Morozov, Alexei V Morozov, Dirk Schürmann, et al.Journal of Immunology (Baltimore, Md. : 1950)|November 23, 2016
Distribution and Activation of CD8+ T Cells in the Duodenal Mucosa before and after HIV SeroconversionKristina Allers, Andreas Puyskens, Hans-Jörg Epple, et al.Antimicrobial Agents and Chemotherapy|November 19, 2008
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjectsPhilippe Colucci, John C Pottage, Heather Robison, et al.BMC Pulmonary Medicine|May 7, 2026
Safety of flexible bronchoscopy in elderly patientsStephanie Spiegel, Ralf-Harto Hübner, Dirk Schürmann, et al.Hepatology (Baltimore, Md.)|November 27, 2004
Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infectionFlorian van Bömmel, Thomas Wünsche, Stefan Mauss, et al.Pageof 5